Spero Therapeutics, Inc. (SPRO)

Spero Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year	Current	2023	2022	2021	2020	2019
Market Capitalization	70	78	90	518	527	184
Market Cap Growth	21.55%	-13.02%	-82.69%	-1.83%	186.63%	64.43%
Enterprise Value	-7	7	-13	378	408	107
PE Ratio	2.97	3.42	-1.93	-5.77	-6.73	-3.02
PS Ratio	0.63	0.75	1.67	28.35	56.50	10.14
PB Ratio	0.73	0.73	1.18	5.86	3.99	2.47
P/FCF Ratio	-6.52	-2.36	-11.59	-8.04	-6.14	-3.65
P/OCF Ratio	-6.52	-2.36	-11.59	-8.04	-6.14	-3.68
EV/Sales Ratio	0.14	0.07	-0.24	20.73	43.74	5.92
EV/EBITDA Ratio	0.60	0.28	0.30	-4.34	-5.26	-1.79
EV/EBIT Ratio	0.60	0.28	0.29	-4.31	-5.21	-1.76
EV/FCF Ratio	-1.10	-0.22	1.67	-5.88	-4.75	-2.13
Debt / Equity Ratio	0.05	0.05	0.09	0.08	0.06	0.07
Debt / EBITDA Ratio	0.20	0.22	-0.15	-0.08	-0.10	-0.09
Debt / FCF Ratio	-0.37	-0.17	-0.86	-0.11	-0.09	-0.11
Quick Ratio	3.82	4.67	5.09	7.98	9.22	3.37
Current Ratio	3.35	3.53	5.25	8.46	9.70	3.58
Asset Turnover	0.80	0.83	0.54	0.13	0.07	0.16
Interest Coverage	-	-	-16.82	-45.27	-	-
Return on Equity (ROE)	30.00%	32.60%	-89.80%	-87.70%	-74.40%	-62.60%
Return on Assets (ROA)	16.80%	18.20%	-46.60%	-62.00%	-60.50%	-52.30%
Return on Capital (ROIC)	19.27%	17.15%	-51.10%	-92.00%	-56.56%	-78.90%
Earnings Yield	33.22%	29.27%	-51.82%	-17.34%	-14.85%	-33.13%
FCF Yield	-20.16%	-42.35%	-8.63%	-12.43%	-16.29%	-27.37%
Buyback Yield / Dilution	-1.90%	-40.98%	-21.65%	-38.01%	-23.27%	-13.49%
Total Shareholder Return	-1.90%	-40.98%	-21.65%	-38.01%	-23.27%	-13.49%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).